Status:
UNKNOWN
Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma
Lead Sponsor:
National Institute of Cancerología
Conditions:
Malignant Pleural Mesothelioma
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Liposomal doxorubicin consists on doxorubicin encapsulated in liposomes that are composed of phosphatidylcholine and cholesterol. Liposomal doxorubicin can extravasate into tumors with abnormal vascul...
Detailed Description
Background: Malignant pleural mesothelioma (MPM) is an invasive primary neoplasm associated with a rapid progression. It is usually diagnosed in the fifth to seventh decades of life, with a strong ma...
Eligibility Criteria
Inclusion
- Patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias
- ECOG functional status 0 or 2
- No renal function alteration (GFR \>50%)
- No hepatic function alteration
- Leucocytes more than 2,000/mcl
- Hemoglobin more than 10mg/dL
- Platelets more than 100,000/mcl
Exclusion
- Patients who had received previous chemotherapy for MPM
- Patients who do not accept the treatment
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00886028
Start Date
September 1 2006
End Date
June 1 2009
Last Update
April 22 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of Cancerología
Mexico City, Mexico City, Mexico, 14080